Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2 R Ligands To Combat Neurodegenerative Disorders.
Dolles D, Nimczick M, Scheiner M, Ramler J, Stadtmüller P, Sawatzky E, Drakopoulos A, Sotriffer C, Wittmann HJ, Strasser A, Decker M. Dolles D, et al. Among authors: scheiner m. ChemMedChem. 2016 Jun 20;11(12):1270-83. doi: 10.1002/cmdc.201500418. Epub 2015 Nov 9. ChemMedChem. 2016. PMID: 26548365
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Hoffmann M, Stiller C, Endres E, Scheiner M, Gunesch S, Sotriffer C, Maurice T, Decker M. Hoffmann M, et al. Among authors: scheiner m. J Med Chem. 2019 Oct 24;62(20):9116-9140. doi: 10.1021/acs.jmedchem.9b01012. Epub 2019 Oct 14. J Med Chem. 2019. PMID: 31609115
Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo.
Scheiner M, Dolles D, Gunesch S, Hoffmann M, Nabissi M, Marinelli O, Naldi M, Bartolini M, Petralla S, Poeta E, Monti B, Falkeis C, Vieth M, Hübner H, Gmeiner P, Maitra R, Maurice T, Decker M. Scheiner M, et al. J Med Chem. 2019 Oct 24;62(20):9078-9102. doi: 10.1021/acs.jmedchem.9b00623. Epub 2019 Oct 14. J Med Chem. 2019. PMID: 31609608 Free PMC article.
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model.
He F, Chou CJ, Scheiner M, Poeta E, Yuan Chen N, Gunesch S, Hoffmann M, Sotriffer C, Monti B, Maurice T, Decker M. He F, et al. Among authors: scheiner m. J Med Chem. 2021 Apr 8;64(7):3794-3812. doi: 10.1021/acs.jmedchem.0c01940. Epub 2021 Mar 26. J Med Chem. 2021. PMID: 33769811
The Structure of Cyclodecatriene Collinolactone, its Biosynthesis, and Semisynthetic Analogues: Effects of Monoastral Phenotype and Protection from Intracellular Oxidative Stress.
Schmid JC, Frey K, Scheiner M, Garzón JFG, Stafforst L, Fricke JN, Schuppe M, Schiewe H, Zeeck A, Weber T, Usón I, Kemkemer R, Decker M, Grond S. Schmid JC, et al. Among authors: scheiner m. Angew Chem Int Ed Engl. 2021 Oct 18;60(43):23212-23216. doi: 10.1002/anie.202106802. Epub 2021 Sep 21. Angew Chem Int Ed Engl. 2021. PMID: 34415670 Free PMC article.
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Pont C, Ginex T, Griñán-Ferré C, Scheiner M, Mattellone A, Martínez N, Arce EM, Soriano-Fernández Y, Naldi M, De Simone A, Barenys M, Gómez-Catalán J, Pérez B, Sabate R, Andrisano V, Loza MI, Brea J, Bartolini M, Bolognesi ML, Decker M, Pallàs M, Luque FJ, Muñoz-Torrero D. Pont C, et al. Among authors: scheiner m. Eur J Med Chem. 2021 Dec 5;225:113779. doi: 10.1016/j.ejmech.2021.113779. Epub 2021 Aug 16. Eur J Med Chem. 2021. PMID: 34418785 Free article.
51 results